key: cord-0310508-wh3k3u28 authors: Yeh, T.-Y.; Contreras, G. P. title: Full vaccination suppresses SARS-CoV-2 delta variant mutation frequency date: 2021-08-10 journal: nan DOI: 10.1101/2021.08.08.21261768 sha: 3ead723139d45e71677c7d6504732f3ca61bc185 doc_id: 310508 cord_uid: wh3k3u28 This study presents the first evidence that full vaccination against COVID-19 suppresses emergent mutations of SARS-CoV-2 delta variants. An evolution algorithm, Tajima D test with a threshold value as -2.50, can provide a promising tool to forecast new COVID-19 outbreaks. Mutations generate different SARS-CoV-2 variants to escape vaccine-mediated immunity and thereby, develop drug or vaccine resistance 1, 2 . Until now, it remained unclear how human interventions (vaccinations, lockdowns, etc.) affected viral mutations. Complete SARS-CoV-2 delta variant sequences from June 20 to July 3 2021: Australia We first analyzed the correlation between the full vaccination rates and Mf of COVID-19 delta variants' genome in 20 countries. We found that Mf was logarithmically reduced as the vaccination rate increased in 16 of the 20 countries All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.08.21261768 doi: medRxiv preprint (R 2 =0.878, Figure 1 ). This is the first evidence that vaccinations successfully suppressed viral mutations. With 10.8% vaccinated rate, Mf was exceptionally low in Australia, likely as a result of the national lockdown restrictions. Mf was higher in Japan, Switzerland, and United States, suggesting that other mitigations may also facilitate suppression of viral mutations. To explore whether mutations evolve randomly, we chronologically analyzed delta variant sequences in the UK, India and Australia with Tajima D' test, which compares pairwise nucleotide diversity (π) and total polymorphism to infer selection and demographic events 5 . π was significantly lower in UK (π< 1.5 × 10 −4 ) than India or Australia (π> 2.0 × 10 −4 ; p<0.01) (Figure 2A Excluding these 4 countries, our data indicates that delta variants evolved to become dominant in inverse correlation to vaccinations. Together with epidemiological reports 2 , we found that one to three weeks after D' reduced to less than -2.50, new COVID-19 outbreaks emerged in India and UK ( Figure 2B ). Although drivers of positive selection (vaccinations, lockdowns, etc.) vary, we propose that a D' score with a threshold of -2.50 is a promising forecasting All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.08.21261768 doi: medRxiv preprint tool for COVID-19 outbreaks. D' of Australian delta variants reached -2.57 on July 3 2021, indicating that lockdowns in Australia were justified to contain outbreaks due to low vaccination rates nationwide. Our data shows that countries with higher vaccination rates generated fewer mutations, suggesting less of a chance for the virus to gain virulent mutations in high vaccinated countries. More virulent SARS-CoV-2 strains have emerged with enhanced transmissibility and immune evasion properties to cause breakthrough infections 6 . We conclude that the virus becomes more contagious as it is screened through the vaccinated population and the resultant strain becomes the dominant strain and able to infect the entire population. We recommend that: 1) universal vaccination should be administered as soon as possible to suppress the generation of virulent mutations; 2) mitigations strategies such as personal protection equipment, social distancing, etc., should continue to be employed to prevent viral transmission until the virus is eradicated; 3) genomic surveillance should be undertaken to monitor for new mutations; and 4) The Tajima D' test provides a tool by which we can forecast future outbreaks. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.08.21261768 doi: medRxiv preprint Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus The World Health organization. Tracking SARS-CoV-2 variants Global Initiative on Sharing All Influenza Data Viral transmission and evolution dynamics of SARS-CoV-2 in shipboard quarantine No potential conflict of interest was reported by the authors. All authors contributed to study concept, rationale, and initial manuscript drafts, interpretation of data, and final manuscript preparation. All authors have read and approved the final version of the manuscript. None declared.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.08.21261768 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.08.21261768 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.08.21261768 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted August 10, 2021. ; https://doi.org/10.1101/2021.08.08.21261768 doi: medRxiv preprint